Mikael Elofsson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3937088/publications.pdf

Version: 2024-02-01

123	5,530	109137	88477
papers	citations	35 h-index	70 g-index

133	133	133	5469
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Exploring divalent conjugates of 5-N-acetyl-neuraminic acid as inhibitors of coxsackievirus A24 variant (CVA24v) transduction. RSC Advances, 2022, 12, 2319-2331.	1.7	0
2	Fluorescent Molecularly Imprinted Polymer Layers against Sialic Acid on Silica-Coated Polystyrene Coresâ€"Assessment of the Binding Behavior to Cancer Cells. Cancers, 2022, 14, 1875.	1.7	7
3	Crystal structures of WrbA, a spurious target of the salicylidene acylhydrazide inhibitors of type III secretion in Gram-negative pathogens, and verification of improved specificity of next-generation compounds. Microbiology (United Kingdom), 2022, 168, .	0.7	1
4	Identification of Small Molecules Blocking the Pseudomonas aeruginosa Type III Secretion System Protein PcrV. Biomolecules, 2021, 11, 55.	1.8	6
5	Sialic Acid as a Biomarker Studied in Breast Cancer Cell Lines In Vitro Using Fluorescent Molecularly Imprinted Polymers. Applied Sciences (Switzerland), 2021, 11, 3256.	1.3	9
6	Synthesis of 4-O-Alkylated N-Acetylneuraminic Acid Derivatives. Journal of Organic Chemistry, 2021, 86, 9145-9154.	1.7	3
7	Exploring the Effect of Structure-Based Scaffold Hopping on the Inhibition of Coxsackievirus A24v Transduction by Pentavalent N-Acetylneuraminic Acid Conjugates. International Journal of Molecular Sciences, 2021, 22, 8418.	1.8	2
8	Pentavalent Sialic Acid Conjugates Block Coxsackievirus A24 Variant and Human Adenovirus Type 37â€"Viruses That Cause Highly Contagious Eye Infections. ACS Chemical Biology, 2020, 15, 2683-2691.	1.6	12
9	Antiviral Activity of Benzavir-2 against Emerging Flaviviruses. Viruses, 2020, 12, 351.	1.5	10
10	Attenuation of Pseudomonas aeruginosa infection by INP0341, a salicylidene acylhydrazide, in a murine model of keratitis. Virulence, 2020, 11, 795-804.	1.8	23
11	Exploring resveratrol dimers as virulence blocking agents â€" Attenuation of type III secretion in Yersinia pseudotuberculosis and Pseudomonas aeruginosa. Scientific Reports, 2020, 10, 2103.	1.6	15
12	Type III secretion inhibitors for the management of bacterial plant diseases. Molecular Plant Pathology, 2019, 20, 20-32.	2.0	31
13	Development, Optimization, and Validation of a High Throughput Screening Assay for Identification of Tat and Type II Secretion Inhibitors of Pseudomonas aeruginosa. Frontiers in Cellular and Infection Microbiology, 2019, 9, 250.	1.8	9
14	Sialic Acid-Containing Glycans as Cellular Receptors for Ocular Human Adenoviruses: Implications for Tropism and Treatment. Viruses, 2019, 11, 395.	1.5	28
15	Corticosteroids protect infected cells against mycobacterial killing inÂvitro. Biochemical and Biophysical Research Communications, 2019, 511, 117-121.	1.0	8
16	PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers. Cell Death and Differentiation, 2019, 26, 1615-1630.	5.0	23
17	Mycobacterium tuberculosis virulence inhibitors discovered by Mycobacterium marinum high-throughput screening. Scientific Reports, 2019, 9, 26.	1.6	15
18	Screening for Inhibitors of Acetaldehyde Dehydrogenase (AdhE) from Enterohemorrhagic Escherichia coli (EHEC). SLAS Discovery, 2018, 23, 815-822.	1.4	3

#	Article	IF	Citations
19	Anti-Rift Valley fever virus activity in vitro, pre-clinical pharmacokinetics and oral bioavailability of benzavir-2, a broad-acting antiviral compound. Scientific Reports, 2018, 8, 1925.	1.6	14
20	Identification of Poly(ADP-Ribose) Polymerase Macrodomain Inhibitors Using an AlphaScreen Protocol. SLAS Discovery, 2018, 23, 353-362.	1.4	23
21	Natural product inspired library synthesis - Identification of 2,3-diarylbenzofuran and 2,3-dihydrobenzofuran based inhibitors of Chlamydia trachomatis. European Journal of Medicinal Chemistry, 2018, 143, 1077-1089.	2.6	34
22	Structureâ€“activity relationships for inhibitors of Pseudomonas aeruginosa exoenzyme S ADP-ribosyltransferase activity. European Journal of Medicinal Chemistry, 2018, 143, 568-576.	2.6	14
23	Cyclopropylmethyl Protection of Phenols: Total Synthesis of the Resveratrol Dimers Anigopreissinâ€…A and Resveratrolâ€“Piceatannol Hybrid. ChemistryOpen, 2018, 7, 953-956.	0.9	4
24	Red Fluorescent Chlamydia trachomatis Applied to Live Cell Imaging and Screening for Antibacterial Agents. Frontiers in Microbiology, 2018, 9, 3151.	1.5	3
25	Synthesis of Indole-, Benzo[b]thiophene-, and Benzo[b]selenophene-Based Analogues of the Resveratrol Dimers Viniferifuran and (Â±)-Dehydroampelopsin B. Organic Letters, 2018, 20, 6650-6654.	2.4	13
26	14-3-3 proteins activate Pseudomonas exotoxins-S and -T by chaperoning a hydrophobic surface. Nature Communications, 2018, 9, 3785.	5.8	37
27	N-aryl 2-aryloxyacetamides as a new class of fatty acid amide hydrolase (FAAH) inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 513-521.	2.5	5
28	The salicylidene acylhydrazide INP0341 attenuates Pseudomonas aeruginosa virulence in vitro and in vivo. Journal of Antibiotics, 2017, 70, 937-943.	1.0	23
29	Diversity-Oriented Synthesis of Libraries Based on Benzofuran and 2,3-Dihydrobenzofuran Scaffolds. ACS Combinatorial Science, 2017, 19, 370-376.	3.8	31
30	Synthesis of 4â€Formylâ€2â€arylbenzofuran Derivatives by PdCl(C₃H₅)dppbâ€Catalyzed Tandem Sonogashira Couplingâ€Cyclization under Microwave Irradiation â€•Application to the Synthesis of Viniferifuran Analogues. ChemistrySelect, 2017, 2, 6245-6248.	0.7	9
31	N-Acylated Derivatives of Sulfamethoxazole Block Chlamydia Fatty Acid Synthesis and Interact with FabF. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	11
32	Total Synthesis of Viniferifuran, Resveratrolâ€Piceatannol Hybrid, Anigopreissin A and Analogues â€“ Investigation of Demethylation Strategies. Advanced Synthesis and Catalysis, 2016, 358, 4085-4092.	2.1	31
33	Total Synthesis of the Resveratrol Oligomers (Â±)â€Ampelopsin B and (Â±)â€µâ€Viniferin. European Journal of Organic Chemistry, 2016, 2016, 426-429.	1.2	34
34	Identification of Inhibitors of Pseudomonas aeruginosa Exotoxin-S ADP-Ribosyltransferase Activity. Journal of Biomolecular Screening, 2016, 21, 590-595.	2.6	12
35	Towards small molecule inhibitors of mono-ADP-ribosyltransferases. European Journal of Medicinal Chemistry, 2015, 95, 546-551.	2.6	46
36	Dibenzocyclooctadiene lignans from Schisandra spp. selectively inhibit the growth of the intracellular bacteria Chlamydia pneumoniae and Chlamydia trachomatis. Journal of Antibiotics, 2015, 68, 609-614.	1.0	30

#	Article	IF	Citations
37	Design, synthesis and evaluation of novel polypharmacological antichlamydial agents. European Journal of Medicinal Chemistry, 2015, 101, 595-603.	2.6	18
38	Triazole linker-based trivalent sialic acid inhibitors of adenovirus type 37 infection of human corneal epithelial cells. Organic and Biomolecular Chemistry, 2015, 13, 9194-9205.	1.5	31
39	Structureâ€“activity relationships for lipoprotein lipase agonists that lower plasma triglycerides inÂvivo. European Journal of Medicinal Chemistry, 2015, 103, 191-209.	2.6	9
40	Novel High-Throughput Screening Method for Identification of Fungal Dimorphism Blockers. Journal of Biomolecular Screening, 2015, 20, 285-291.	2.6	16
41	Inhibitory Activity of the Isoflavone Biochanin A on Intracellular Bacteria of Genus Chlamydia and Initial Development of a Buccal Formulation. PLoS ONE, 2014, 9, e115115.	1.1	54
42	N -Acylated Derivatives of Sulfamethoxazole and Sulfafurazole Inhibit Intracellular Growth of Chlamydia trachomatis. Antimicrobial Agents and Chemotherapy, 2014, 58, 2968-2971.	1.4	38
43	The gallium(III)â€“salicylidene acylhydrazide complex shows synergistic anti-biofilm effect and inhibits toxin production by Pseudomonas aeruginosa. Journal of Inorganic Biochemistry, 2014, 138, 1-8.	1.5	20
44	Solving the Supply of Resveratrol Tetramers from Papua New Guinean Rainforest Anisoptera Species That Inhibit Bacterial Type III Secretion Systems. Journal of Natural Products, 2014, 77, 2633-2640.	1.5	16
45	Design of a Generalâ€Purpose European Compound Screening Library for EUâ€OPENSCREEN. ChemMedChem, 2014, 9, 2309-2326.	1.6	29
46	Identification of a small molecule that stabilizes lipoprotein lipase in vitro and lowers triglycerides in vivo. Biochemical and Biophysical Research Communications, 2014, 450, 1063-1069.	1.0	17
47	Screening for Inhibition of Vibrio cholerae VipA-VipB Interaction Identifies Small-Molecule Compounds Active against Type VI Secretion. Antimicrobial Agents and Chemotherapy, 2014, 58, 4123-4130.	1.4	13
48	Benzylidene Acylhydrazides Inhibit Chlamydial Growth in a Type III Secretion- and Iron Chelation-Independent Manner. Journal of Bacteriology, 2014, 196, 2989-3001.	1.0	29
49	Isolation and Characterization of Anti-Adenoviral Secondary Metabolites from Marine Actinobacteria. Marine Drugs, 2014, 12, 799-821.	2.2	25
50	Statistical Molecular Design: A Tool to Follow Up Hits from Small-Molecule Screening. Methods in Molecular Biology, 2014, 1056, 169-188.	0.4	0
51	Chemical Probes to Study ADP-Ribosylation: Synthesis and Biochemical Evaluation of Inhibitors of the Human ADP-Ribosyltransferase ARTD3/PARP3. Journal of Medicinal Chemistry, 2013, 56, 9556-9568.	2.9	9
52	PARP Inhibitor with Selectivity Toward ADP-Ribosyltransferase ARTD3/PARP3. ACS Chemical Biology, 2013, 8, 1698-1703.	1.6	48
53	Mutations in hemG Mediate Resistance to Salicylidene Acylhydrazides, Demonstrating a Novel Link between Protoporphyrinogen Oxidase (HemG) and Chlamydia trachomatis Infectivity. Journal of Bacteriology, 2013, 195, 4221-4230.	1.0	41
54	The Resveratrol Tetramer (-)-Hopeaphenol Inhibits Type III Secretion in the Gram-Negative Pathogens Yersinia pseudotuberculosis and Pseudomonas aeruginosa. PLoS ONE, 2013, 8, e81969.	1.1	69

#	Article	IF	Citations
55	Pre-clinical pharmacokinetics and anti-chlamydial activity of salicylidene acylhydrazide inhibitors of bacterial type III secretion. Journal of Antibiotics, 2012, 65, 397-404.	1.0	39
56	Syntheses of pseudoceramines Aâ€“D and a new synthesis of spermatinamine, bromotyrosine natural products from marine sponges. Organic and Biomolecular Chemistry, 2012, 10, 1246-1254.	1.5	12
57	2-[4,5-Difluoro-2-(2-Fluorobenzoylamino)-Benzoylamino]Benzoic Acid, an Antiviral Compound with Activity against Acyclovir-Resistant Isolates of Herpes Simplex Virus Types 1 and 2. Antimicrobial Agents and Chemotherapy, 2012, 56, 5735-5743.	1.4	15
58	Synthesis, Biological Evaluation, and Structureâ€“Activity Relationships of 2-[2-(Benzoylamino)benzoylamino]benzoic Acid Analogues as Inhibitors of Adenovirus Replication. Journal of Medicinal Chemistry, 2012, 55, 3170-3181.	2.9	24
59	Small Molecule Screening for Inhibitors of the YopH Phosphatase of Yersinia pseudotuberculosis. Advances in Experimental Medicine and Biology, 2012, 954, 357-363.	0.8	3
60	In vitro anti-HIV-1 activity of salicylidene acylhydrazide compounds. International Journal of Antimicrobial Agents, 2012, 40, 354-360.	1.1	6
61	Structural Characterisation of Tpx from Yersinia pseudotuberculosis Reveals Insights into the Binding of Salicylidene Acylhydrazide Compounds. PLoS ONE, 2012, 7, e32217.	1.1	17
62	Discovery of Ligands for ADP-Ribosyltransferases via Docking-Based Virtual Screening. Journal of Medicinal Chemistry, 2012, 55, 7706-7718.	2.9	37
63	Derivatives of 8-hydroxyquinolineâ€”antibacterial agents that target intra- and extracellular Gram-negative pathogens. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3550-3553.	1.0	57
64	Preliminary Pharmacokinetics of the Bacterial Virulence Inhibitor Nâ€²-(3,5-Dibromo-2-Hydroxy-Benzylidenene)-Nicotinic Acid Hydrazide. Advances in Experimental Medicine and Biology, 2012, 954, 349-356.	0.8	4
65	Pseudoceramines Aâ€“D, new antibacterial bromotyrosine alkaloids from the marine sponge Pseudoceratina sp.. Organic and Biomolecular Chemistry, 2011, 9, 6755.	1.5	49
66	Identification of Bacterial Target Proteins for the Salicylidene Acylhydrazide Class of Virulence-blocking Compounds. Journal of Biological Chemistry, 2011, 286, 29922-29931.	1.6	94
67	Protection of Mice From a Chlamydia trachomatis Vaginal Infection Using a Salicylidene Acylhydrazide, a Potential Microbicide. Journal of Infectious Diseases, 2011, 204, 1313-1320.	1.9	38
68	A Potent Trivalent Sialic Acid Inhibitor of Adenovirus Type 37 Infection of Human Corneal Cells. Angewandte Chemie - International Edition, 2011, 50, 6519-6521.	7.2	36
69	Synthesis of [4-(2-Hydroxyphenyl)thiazol-2-yl]methanones as Potential Bioisosteres of Salicylidene Acylhydrazides. Molecules, 2010, 15, 6019-6034.	1.7	4
70	Statistical molecular design of a focused salicylidene acylhydrazide library and multivariate QSAR of inhibition of type III secretion in the Gram-negative bacterium Yersinia. Bioorganic and Medicinal Chemistry, 2010, 18, 2686-2703.	1.4	63
71	Expression, purification, crystallization and initial X-ray diffraction analysis of thiol peroxidase fromYersinia pseudotuberculosis. Acta Crystallographica Section F: Structural Biology Communications, 2010, 66, 1606-1609.	0.7	6
72	Synthesis and Application of a 2-[(4-Fluorophenyl)-sulfonyl]ethoxy Carbonyl(Fsec) Protected Glycosyl Donor in Carbohydrate Chemistry. Molecules, 2010, 15, 5708-5720.	1.7	1

#	Article	IF	Citations
73	Small-Molecule Screening Using a Whole-Cell Viral Replication Reporter Gene Assay Identifies 2-{[2-(Benzoylamino)Benzoyl]Amino}-Benzoic Acid as a Novel Antiadenoviral Compound. Antimicrobial Agents and Chemotherapy, 2010, 54, 3871-3877.	1.4	22
74	Candidate vaginal microbicides with activity against Chlamydia trachomatis and Neisseriagonorrhoeae. International Journal of Antimicrobial Agents, 2010, 36, 145-150.	1.1	32
75	Synthesis of 2-(2-Aminopyrimidine)-2,2-difluoroethanols as Potential Bioisosters of Salicylidene Acylhydrazides. Molecules, 2010, 15, 4423-4438.	1.7	7
76	Statistical Molecular Design of Balanced Compound Libraries for QSAR Modeling. Current Medicinal Chemistry, 2010, 17, 2001-2016.	1.2	18
77	Carbamate Linker Strategy in Solidâ€Phase Synthesis of Aminoâ€Functionalized Glycoconjugates for Attachment to Solid Surfaces and Investigation of Proteinâ€Carbohydrate Interactions. European Journal of Organic Chemistry, 2009, 2009, 349-357.	1.2	6
78	Synthesis and application of Nâ€[1â€(4â€(4â€fluorophenyl)â€2,6â€dioxocyclohexylidene)ethyl](Fde)â€protected amino acids for optimization of solidâ€phase peptide synthesis using gelâ€phase ¹⁹F NMR spectroscopy. Journal of Peptide Science, 2009, 15, 264-271.	0.8	1
79	Design, Synthesis, and Evaluation of N-Acyl Modified Sialic Acids as Inhibitors of Adenoviruses Causing Epidemic Keratoconjunctivitis. Journal of Medicinal Chemistry, 2009, 52, 3666-3678.	2.9	10
80	Characterization of the Effects of Salicylidene Acylhydrazide Compounds on Type III Secretion in Escherichia coli O157:H7. Infection and Immunity, 2009, 77, 4209-4220.	1.0	63
81	Virulence blockers as alternatives to antibiotics: type III secretion inhibitors against Gramâ€negative bacteria. Journal of Internal Medicine, 2008, 264, 17-29.	2.7	133
82	Reversal of the Antichlamydial Activity of Putative Type III Secretion Inhibitors by Iron. Infection and Immunity, 2007, 75, 3478-3489.	1.0	71
83	Inhibition of Type III Secretion in Salmonella enterica Serovar Typhimurium by Small-Molecule Inhibitors. Antimicrobial Agents and Chemotherapy, 2007, 51, 2631-2635.	1.4	129
84	Small molecule inhibitors of type III secretion inYersiniablock theChlamydia pneumoniaeinfection cycle. FEBS Letters, 2007, 581, 587-595.	1.3	94
85	Salicylidene Acylhydrazides That Affect Type III Protein Secretion in Salmonella enterica Serovar Typhimurium. Antimicrobial Agents and Chemotherapy, 2007, 51, 2867-2876.	1.4	105
86	Synthesis and evaluation of 2-(2-fluoro-4-hydroxymethyl-5-methoxy-phenoxy)acetic acid as a linker in solid-phase synthesis monitored by gel-phase19F NMR spectroscopy. Organic and Biomolecular Chemistry, 2007, 5, 2464-2471.	1.5	7
87	Design, Synthesis, and Multivariate Quantitative Structureâ€'Activity Relationship of SalicylanilidesPotent Inhibitors of Type III Secretion in Yersinia. Journal of Medicinal Chemistry, 2007, 50, 6177-6188.	2.9	66
88	Inhibitors of type III secretion in Yersinia: Design, synthesis and multivariate QSAR of 2-arylsulfonylamino-benzanilides. Bioorganic and Medicinal Chemistry, 2007, 15, 6994-7011.	1.4	26
89	Application of gel-phase19F NMR spectroscopy for optimization of solid-phase synthesis of a hydrophobic peptide from the signal sequence of the mucin MUC1. Journal of Peptide Science, 2007, 13, 354-361.	0.8	6
90	Multivalent sialic acid conjugates inhibit adenovirus type 37 from binding to and infecting human corneal epithelial cells. Antiviral Research, 2007, 73, 92-100.	1.9	35

#	Article	IF	Citations
91	Formation of lactones from sialylated MUC1 glycopeptides. Organic and Biomolecular Chemistry, 2006, 4, 713.	1.5	17
92	NMR Tube Filter Reactor for Solid-Phase Synthesis and Gel-Phase19F NMR Spectroscopy. ACS Combinatorial Science, 2006, 8, 150-152.	3.3	5
93	A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14566-14571.	3.3	181
94	Multivalent HSA Conjugates of 3â€²-Sialyllactose are Potent Inhibitors of Adenoviral Cell Attachment and Infection. ChemBioChem, 2005, 6, 358-364.	1.3	33
95	Small-Molecule Inhibitors Specifically Targeting Type III Secretion. Infection and Immunity, 2005, 73, 3104-3114.	1.0	197
96	Solid-phase synthesis of serine-based glycosphingolipid analogues for preparation of glycoconjugate arrays. Organic and Biomolecular Chemistry, 2005, 3, 309.	1.5	11
97	Loading of the Antigen-Presenting Protein CD1d with Synthetic Glycolipids. ChemBioChem, 2004, 5, 437-444.	1.3	8
98	Gel-phase19F NMR spectral quality for resins commonly used in solid-phase organic synthesis; a study of peptide solid-phase glycosylations. Organic and Biomolecular Chemistry, 2004, 2, 1770-1776.	1.5	18
99	A Fluorinated Selenide Linker for Solid-Phase Synthesis ofn-Pentenyl Glycosides. Organic Letters, 2004, 6, 4885-4888.	2.4	18
100	Targeting Bacterial Virulence. Chemistry and Biology, 2003, 10, 241-249.	6.2	206
101	Solid-Phase Synthesis of Î±-Gal Epitopes:Â On-Resin Analysis of Solid-Phase Oligosaccharide Synthesis with19F NMR Spectroscopy. Journal of Organic Chemistry, 2003, 68, 7281-7288.	1.7	34
102	Salicylanilides are Potent Inhibitors of Type III Secretion in Yersinia. , 2003, 529, 97-100.		28
103	Characterization of a Novel Mammalian Phosphatase Having Sequence Similarity toSchizosaccharomyces pombePHO2 andSaccharomyces cerevisiaePHO13â€. Biochemistry, 2002, 41, 7841-7848.	1.2	10
104	Fluorinated Protective Groups for On-Resin Quantification of Solid-Phase Oligosaccharide Synthesis with19F NMR Spectroscopy. ChemBioChem, 2002, 3, 1266-1269.	1.3	18
105	Monitoring Solid-Phase Glycoside Synthesis with19F NMR Spectroscopy. Organic Letters, 2001, 3, 1463-1466.	2.4	35
106	The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IÎºB kinase. Chemistry and Biology, 2001, 8, 759-766.	6.2	456
107	Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 10403-10408.	3.3	881
108	Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide Î±', Î²'-epoxyketones. Chemistry and Biology, 1999, 6, 811-822.	6.2	141

#	Article	IF	Citations
109	Total synthesis of the-potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 2283-2288.	1.0	197
110	[11] Direct synthesis of glycosylated amino acids from carbohydrate peracetates and Fmoc amino acids: Solid-phase synthesis of biomedicinally interesting glycopeptides. Methods in Enzymology, 1997, 289, 221-245.	0.4	23
111	Preparation of Tn and sialyl Tn building blocks used in Fmoc solid-phase synthesis of glycopeptide fragments from HIV gp120. Tetrahedron, 1997, 53, 369-390.	1.0	77
112	Solid-Phase Synthesis of Glycopeptides: Immunological Studies with T Cell Stimulating Glycopeptides. Current Medicinal Chemistry, 1997, 4, 85-116.	1.2	54
113	Removal of Acyl Protective Groups from Glycopeptides:Â Base Does Not Epimerize Peptide Stereocenters, and Î²-Elimination Is Slow. Journal of Organic Chemistry, 1996, 61, 560-565.	1.7	74
114	Preparation and structural characterization of N-glycated amino acid and linear or cyclic dipeptides containing the 6-amino-6-deoxy-1,2:3,4-di-O-isopropylidene-Î±-d-galactopyranose moiety. Carbohydrate Research, 1996, 287, 1-19.	1.1	11
115	Building blocks for glycopeptide synthesis: Preparation of Î±-O-fucosylated fmoc serine and threonine in one step from L-fucose tetraacetate. Tetrahedron Letters, 1996, 37, 7645-7648.	0.7	21
116	Solidâ€phase synthesis and conformational studies of helper T cell immunogenic peptides that carry carbohydrate haptens linked to serine. International Journal of Peptide and Protein Research, 1996, 47, 340-347.	0.1	7
117	Preparation of building blocks for glycopeptide synthesis by glycosylation of Fmoc amino acids having unprotected carboxyl groups. Tetrahedron, 1995, 51, 5643-5656.	1.0	97
118	Synthesis of Tn and sialyl Tn building blocks for solid phase glycopeptide synthesis. Tetrahedron Letters, 1995, 36, 7499-7502.	0.7	19
119	Synthesis of a water-soluble serine-based neoglycolipid which can be covalently linked to solid phases. Carbohydrate Research, 1994, 258, 123-133.	1.1	8
120	Solid-phase synthesis and conformational studies of glycosylated derivatives of helper-T-cell immunogenic peptides from hen-egg lysozyme. Carbohydrate Research, 1993, 246, 89-103.	1.1	31
121	A carbohydrate antigen linked to a T-cell immunogenic peptide induces T-cell clones selective for carbohydrate. , 1993, , 840-841.		0
122	Building blocks for glycopeptide synthesis: glycosylation of 3-mercaptopropionic acid and Fmoc amino acids with unprotected carboxyl groups. Tetrahedron Letters, 1991, 32, 7613-7616.	0.7	91
123	Derivatization Procedures for Reducing Oligosaccharides, Part 3: Preparation of Oligosaccharide Glycosylamines, and Their Conversion Into Glycosaccharide - Acrylamide Copolymers. Journal of Carbohydrate Chemistry, 1989, 8, 597-611.	0.4	119